Powder properties and their influence on dry powder inhaler delivery of an antitubercular drug

被引:0
|
作者
Sethuraman V.V. [1 ]
Hickey A.J. [2 ]
机构
[1] Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill
[2] School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill
关键词
Aerosol dispersion; Cohesive energy density; Dry powder inhalers; Surface area; Surface energy;
D O I
10.1208/pt030428
中图分类号
学科分类号
摘要
The purpose of this study was to determine if aerosol delivery of drug loaded microparticles to lungs infected with Mycobacterium tuberculosis may be achieved by predicting dispersion of dry powders through knowledge of particle surface properties. Particle sizes of rifampicin-loaded poly (lactide-co-glycolide) microparticles (R-PLGA), rifampicin alone, and lactose and maltodextrin carrier particles (bulk and 75-125-μ sieved fractions) were determined by electron microscopy for the projected area diameter (Dp) and laser diffraction for the volume diameter (Dv). Surface energies (y) of R-PLGA, rifampicin alone, lactose, and maltodextrin were obtained by inverse phase gas chromatography, surface areas (Sa) by N2 adsorption, and cohesive energy densities by calculation. Particle dispersion was evaluated (Andersen nonviable impactor) for 10% blends of R-PLGA and rifampicin alone with bulk and sieved fractions of the carriers. Dp for R-PLGA and rifampicin alone was 3.02 and 2.83 μm, respectively. Dv was 13 ± 1 and 2 ± 1 μm for R-PLGA and rifampicin alone, respectively, indicating that R-PLGA was more aggregated. This was evident in y of 35 ± 1 and 19 ± 6 mJ/m 2 for RPLGA and rifampicin alone. Dp for lactose and maltodextrin (sieved and bulk) was approximately 40 mm. Bulk maltodextrin (Dv = 119 ± 6 mm) was more aggregated than bulk lactose (Dv = 54 ± 2 mm). This was a result of the higher Sa for maltodextrin (0.54 m2/g) than for lactose (0.21 m2/g). The y of bulk lactose and maltodextrin was 40 ± 4 and 60 ± 6 mJ/m 2 and of sieved lactose and maltodextrin was 39 ± 1 and 50 ± 1 mJ/m2. Impaction studies yielded higher fine particle fractions of R-PLGA from sieved lactose, 13% ± 3%, than from sieved maltodextrin, 7% ± 1%, at 90 L/min. An expression, based on these data, is proposed as a predictor of drug dispersion from carrier particles. Delivery of dry powder formulations can be achieved by characterizing particle surfaces and predicting impact on dispersion.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere® powder
    Duddu, SP
    Sisk, SA
    Walter, YH
    Tarara, TE
    Trimble, KR
    Clark, AR
    Eldon, MA
    Elton, RC
    Pickford, M
    Hirst, PH
    Newman, SP
    Weers, JG
    PHARMACEUTICAL RESEARCH, 2002, 19 (05) : 689 - 695
  • [32] Dry powder inhalers of antitubercular drugs
    Nainwal, Nidhi
    Sharma, Yuwanshi
    Jakhmola, Vikash
    TUBERCULOSIS, 2022, 135
  • [33] Dry powder inhaler device influence on carrier particle performance
    Donovan, Martin J.
    Kim, Sin Hyen
    Raman, Venkatramanan
    Smyth, Hugh D.
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (03) : 1097 - 1107
  • [34] Dry powder drug delivery devices for asthma
    Shepherd, Michael T., 1600, John Wiley & Sons Ltd, Chichester, United Kingdom (07):
  • [35] INFLUENCE OF STORAGE CONDITIONS ON TERNARY DRY POWDER INHALER FORMULATIONS
    Hertel, M.
    Schwarz, E.
    Kobler, M.
    Hauptstein, S.
    Steckel, H.
    Scherliess, R.
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2018, 31 (02) : A4 - A4
  • [36] Devices for Dry Powder Drug Delivery to the Lung
    Berkenfeld, Kai
    Lamprecht, Alf
    McConville, Jason T.
    AAPS PHARMSCITECH, 2015, 16 (03): : 479 - 490
  • [37] Effervescent dry powder for respiratory drug delivery
    Ely, Leticia
    Roa, Wilson
    Finlay, Warren H.
    Lobenberg, Raimar
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2007, 65 (03) : 346 - 353
  • [38] Devices for Dry Powder Drug Delivery to the Lung
    Kai Berkenfeld
    Alf Lamprecht
    Jason T. McConville
    AAPS PharmSciTech, 2015, 16 : 479 - 490
  • [39] Dry powder platform for pulmonary drug delivery
    Derek Ivan Daniher
    Jesse Zhu
    Particuology, 2008, (04) : 225 - 238
  • [40] Dry powder platform for pulmonary drug delivery
    Daniher, Derek Ivan
    Zhu, Jesse
    PARTICUOLOGY, 2008, 6 (04) : 225 - 238